AIM ImmunoTech's Ampligen Shows Early Promise in Pancreatic Cancer Trial
Event summary
- AIM ImmunoTech reported positive mid-year interim results from its Phase 2 DURIPANC study evaluating Ampligen in combination with AstraZeneca’s Imfinzi for pancreatic cancer.
- The study, a collaboration with AstraZeneca and Erasmus Medical Center, is on track for primary endpoint evaluation in December 2026.
- Previous Named Patient Program data showed Ampligen extended median survival to 19.7 months compared to 8.6 months with standard care.
- AIM plans to initiate a Phase 3 trial evaluating Ampligen with a PD-1 inhibitor, targeting overall and progression-free survival.
The big picture
AIM ImmunoTech’s progress in pancreatic cancer research comes as the biotech sector intensifies efforts to improve outcomes for aggressive cancers. The company’s focus on combination therapies aligns with broader industry trends favoring immuno-oncology approaches. Success in this trial could position AIM as a key player in pancreatic cancer treatment, though it faces stiff competition from established players like AstraZeneca and Merck.
What we're watching
- Clinical Validation
- Whether Ampligen’s combination therapy can demonstrate significant survival benefits in the Phase 3 trial.
- Regulatory Pathway
- The pace at which AIM can secure approvals for Ampligen as a standard treatment for pancreatic cancer.
- Competitive Positioning
- How AIM differentiates Ampligen in a crowded oncology market with existing PD-1/PD-L1 inhibitors.